- Trials with a EudraCT protocol (1,377)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6,518)
1,377 result(s) found for: Ph.
Displaying page 1 of 69.
EudraCT Number: 2020-002537-15 | Sponsor Protocol Number: R10933-10987-COV-2066 | Start Date*: 2020-10-06 | ||||||||||||||||
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS CoV 2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19 | ||||||||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002067-18 | Sponsor Protocol Number: B12CS-B13CS | Start Date*: 2018-12-11 | |||||||||||
Sponsor Name:Advicenne | |||||||||||||
Full Title: A multicentre, randomised, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability and acceptability of repeated doses... | |||||||||||||
Medical condition: Cystinuria | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003158-15 | Sponsor Protocol Number: GA1406 | Start Date*: 2014-10-10 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A randomised, assessor blind, placebo controlled exploratory study in healthy volunteers, to characterise the acid neutralisation activity of sodium alginate oral suspension in the fasted state, us... | ||
Medical condition: To pilot the use of a custom designed pH catheter for the measurement of intragastric pH to characterise the antacid action of Gaviscon Double Action versus placebo. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004725-27 | Sponsor Protocol Number: GA1109 | Start Date*: 2012-01-24 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd | ||
Full Title: A single-centre, randomised, double-blind, two-way crossover, placebo-controlled pilot study, investigating the use of a novel intragastric and oesophageal pH catheter to characterise the antacid a... | ||
Medical condition: To pilot the use of a novel pH catheter for the measurement of oesophageal and intragastric pH comparing the onset and duration of antacid action of Gaviscon Double Action versus placebo. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000539-42 | Sponsor Protocol Number: RB2-NL-1518 | Start Date*: 2016-04-15 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th... | ||
Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-004131-23 | Sponsor Protocol Number: GA1212 | Start Date*: 2013-01-18 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd | ||
Full Title: A single-centre, randomised, 2 way crossover, double blind, placebo controlled study in healthy volunteers, to characterise the antacid activity of Gaviscon Double Action Mint Liquid in the fasted ... | ||
Medical condition: This study is to demonstrate the antacid action of Gaviscon Double Action Mint versus a matched placebo using a pH catheter. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-006726-26 | Sponsor Protocol Number: 101266 | Start Date*: 2007-03-05 |
Sponsor Name:Orexo AB | ||
Full Title: An open-label randomised observer-blind study to evaluate 24-hour intragastric pH profile at day 1 and day 14 during treatment with a fixed combination of a histamine type 2 receptor antagonist and... | ||
Medical condition: Frequent heartburn | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-014539-20 | Sponsor Protocol Number: IGA-10612-3 | Start Date*: 2009-08-24 |
Sponsor Name:University Hospital Ostrava | ||
Full Title: The Position of Outpatient 24-Hour Dual-Probe pH-metry in the Diagnostics of Extraosophageal Reflux | ||
Medical condition: Ve studii budeme zkoumat extraezofageální reflux, jedná se o podskupinu refluxní nemoci jícnu, kdy jsou v popředí mimojícnové projevy kyselého refluxu. Závěry studií uzavírají, že EER v různé míře ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-020153-14 | Sponsor Protocol Number: HFpEF | Start Date*: 2011-01-12 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Effects of Sildenafil on pulmonary artery pressure in patients with heart failure with preserved ejection fraction and pulmonary hypertension | ||
Medical condition: The condition to be investigated is isolated left heart failure , also called heart failure with preserved ejection fraction ( HFpEF) with pulmonary hypertension. HFpEF is a clinical syndrome wit... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-022945-52 | Sponsor Protocol Number: ADVL0516 | Start Date*: 2012-01-26 | ||||||||||||||||
Sponsor Name:Children’s Oncology Group | ||||||||||||||||||
Full Title: A Phase 1 Study of BMS-354825 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia. | ||||||||||||||||||
Medical condition: Refractory solid tumors Ph+ leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-001950-45 | Sponsor Protocol Number: INS1009-212 | Start Date*: 2023-02-14 | ||||||||||||||||||||||||||
Sponsor Name:INSMED INCORPORATED | ||||||||||||||||||||||||||||
Full Title: An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Assoc... | ||||||||||||||||||||||||||||
Medical condition: Pulmonary Hypertension Associated with Interstitial Lung Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Ongoing) DE (Ongoing) ES (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001805-34 | Sponsor Protocol Number: CSTI571I1203 | Start Date*: 2017-08-15 |
Sponsor Name:Novartis Pharma K.K | ||
Full Title: Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia | ||
Medical condition: Philadelphia Chromosome Positive Acute Lymphocytic Leukemia (Ph+ALL) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2012-000678-44 | Sponsor Protocol Number: GA1116 | Start Date*: 2012-09-04 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd | ||
Full Title: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj... | ||
Medical condition: A single-centre, randomised, four-way crossover study to investigate the measurement of the acid pocket and subsequent gastro-oesophageal reflux episodes using a novel pH/impedance catheter in subj... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-004109-28 | Sponsor Protocol Number: GA1211 | Start Date*: 2013-01-18 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd | ||
Full Title: A randomised, 4 way crossover, double blind, placebo controlled pilot study in patients with reflux symptoms, to assess suppression of gastro-oesophageal reflux by ‘Gaviscon Double Action Mint ’ us... | ||
Medical condition: This study assesses suppression of gastro-oesophageal reflux of Gaviscon in patients with gastro-oesophageal reflux disease. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2008-002260-33 | Sponsor Protocol Number: CA180-226 | Start Date*: 2009-02-16 | |||||||||||
Sponsor Name:Bristol-Myers Squibb Internaltional Corporation | |||||||||||||
Full Title: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib Revised... | |||||||||||||
Medical condition: Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Ongoing) FR (Ongoing) NL (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004780-52 | Sponsor Protocol Number: 20180257 | Start Date*: 2020-06-05 | ||||||||||||||||
Sponsor Name:Amgen Inc. | ||||||||||||||||||
Full Title: A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of adults with Relapsed or Refractory B cell ... | ||||||||||||||||||
Medical condition: Adults with relapsed or refractory B-precursor ALL (R/R B-ALL) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Completed) NL (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018419-14 | Sponsor Protocol Number: CAMN107A2120 | Start Date*: 2010-10-27 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multi-center, open-label, pharmacokinetic study of oral nilotinib in pediatric patients with Gleevec® (imatinib)-resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with ... | |||||||||||||
Medical condition: pediatric patients with Gleevec® (imatinib)- resistant/intolerant Ph+ CML chronic phase (CP) or accelerated phase (AP) or with refractory/relapsed Ph+ ALL | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) DE (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000705-20 | Sponsor Protocol Number: EsPhALL2017/COGAALL1631 | Start Date*: 2017-12-11 | ||||||||||||||||
Sponsor Name:Università degli Studi Milano Bicocca | ||||||||||||||||||
Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones | ||||||||||||||||||
Medical condition: Philadelphia positive Acute Lumphoblastic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Ongoing) IT (Ongoing) NL (Ongoing) CZ (Ongoing) DE (Ongoing) FI (Ongoing) BE (Ongoing) SE (Ongoing) PL (Ongoing) DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001279-39 | Sponsor Protocol Number: CA180-083 | Start Date*: 2006-09-15 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant... | ||
Medical condition: Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) CZ (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-003250-25 | Sponsor Protocol Number: B1871039 | Start Date*: 2014-06-24 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors | |||||||||||||
Medical condition: Philadelphia Chromosome Positive Chronic Myeloid Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) DE (Prematurely Ended) IT (Completed) BE (Completed) NL (Completed) ES (Completed) AT (Completed) NO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.